FORXIGA™ approved in EU for treatment of T2D

FORXIGA is a selective and reversible inhibitor of sodium-glucose cotransporter 2 (SGLT2) that works independently of insulin to help remove excess glucose from the body, a unique mode of action not seen in any other currently available treatments for type 2 diabetes (AstraZeneca and Bristol-Myers Squibb)